Sintilimab after esophageal surgery to help prevent cancer return
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell cancer confirmed by pathology (tissue test).
- Your cancer is in the chest part of the esophagus (thoracic oesophagus).
- You are age 18 to 70, and you can do most daily activities (ECOG 0 to 1).
- Your cancer was fully removed with surgery (R0 resection), with a lymph node dissection that included at least 15 lymph nodes.
- You did NOT get neoadjuvant chemoradiation (chemo plus radiation) before surgery, and you did NOT have an immunotherapy drug before.
- Your blood counts, liver, kidneys, and thyroid are in acceptable ranges, and you can safely take the trial drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial tests a short course of radiation combined with an immunotherapy drug called sintilimab before surgery for esophageal squamous cell carcinoma. The goal is to see if this combination can shrink the tumor and improve treatment outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.